Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview
Lysine-specific demethylase 1 (LSD1) was the first histone demethylase discovered and conserved from fission yeast (S. pombe) to mammals. LSD1 played a pivotal role in a variety of biological processes like cell proliferation, adipogenesis, spermatogenesis, chromosome segregation, pluripotency regulation of stem cell and embryonic development. The discovery of LSD1 in 2004 demonstrated for the first time that histone methylation is a reversible reaction. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. Upon specific stimulation, LSD1 can also act as a transcriptional co-activator. LSD1 is structurally similar to the Flavin-dependent monoamine oxidases (MAOs). Both LSD1 and MAOs utilize flavin adenine dinucleotide (FAD) as cofactor, thus, a number of known MAO inhibitors have been shown to also inhibit LSD1 through irreversible interaction of FAD. The overexpression of LSD1 is reported to be associated with different malignancies. Therefore, the inhibition of LSD1 provides a promising pharmacological target to investigate novel treatments for cancer and other disorders that associate with LSD1’s activity.
Report Highlights
This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs.
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview
Lysine-specific demethylase 1 (LSD1) was the first histone demethylase discovered and conserved from fission yeast (S. pombe) to mammals. LSD1 played a pivotal role in a variety of biological processes like cell proliferation, adipogenesis, spermatogenesis, chromosome segregation, pluripotency regulation of stem cell and embryonic development. The discovery of LSD1 in 2004 demonstrated for the first time that histone methylation is a reversible reaction. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. Upon specific stimulation, LSD1 can also act as a transcriptional co-activator. LSD1 is structurally similar to the Flavin-dependent monoamine oxidases (MAOs). Both LSD1 and MAOs utilize flavin adenine dinucleotide (FAD) as cofactor, thus, a number of known MAO inhibitors have been shown to also inhibit LSD1 through irreversible interaction of FAD. The overexpression of LSD1 is reported to be associated with different malignancies. Therefore, the inhibition of LSD1 provides a promising pharmacological target to investigate novel treatments for cancer and other disorders that associate with LSD1’s activity.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lysine Specific Demethylase 1 (LSD-1) Inhibitor R&D. The therapies under development are focused on novel approaches for Lysine Specific Demethylase 1 (LSD-1) Inhibitor.
This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs
- ORY-2001: Oryzon Genomics
- Domatinostat: 4SC
Further product details are provided in the report……..
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Lysine Specific Demethylase 1 (LSD-1) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs.
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Insights
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs?
- How many Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Lysine Specific Demethylase 1 (LSD-1) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lysine Specific Demethylase 1 (LSD-1) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Oryzon Genomics
- 4SC
- Salarius Pharmaceuticals
- Celgene Corporation
- Taiho Pharmaceutical
- CSPC ZhongQi Pharmaceutical Technology
- Beatica
- Rasna Therapeutics
- ORY-2001
- Domatinostat
- ORY-3001
- Seclidemstat
- CC-90011
- TAS-1440
- SYHA-1807
- Research programme: small molecule therapeutics
- RASP-201
Introduction
Executive Summary
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
Lysine Specific Demethylase 1 (LSD-1) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Lysine Specific Demethylase 1 (LSD-1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ORY-2001: Oryzon Genomics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
Seclidemstat: Salarius Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme - small molecule therapeutics: Beatica
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Products
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Unmet Needs
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Market Drivers and Barriers
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Future Perspectives and Conclusion
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Analyst Views
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Appendix
Executive Summary
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
Lysine Specific Demethylase 1 (LSD-1) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Lysine Specific Demethylase 1 (LSD-1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ORY-2001: Oryzon Genomics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
Seclidemstat: Salarius Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme - small molecule therapeutics: Beatica
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Products
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Unmet Needs
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Market Drivers and Barriers
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Future Perspectives and Conclusion
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Analyst Views
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Lysine specific demethylase 1 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Lysine specific demethylase 1 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Lysine specific demethylase 1 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Lysine specific demethylase 1 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
